RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
Clinical trial NCT05957757 · UNKNOWN
Trial details
- NCT number
- NCT05957757
- Sponsor
- RenJi Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-05
- Primary completion
- 2026-06-08
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.